AI assistant
DEXCOM INC — Director's Dealing 2017
Aug 24, 2017
30198_dirs_2017-08-24_8837c224-0d42-4fb0-b80c-fe3a2ee1c470.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2017-08-23
Reporting Person: DOUBLEDAY RICHARD (EVP, Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-08-23 | Common Stock | S | 1635 | $75.2617 | Disposed | 23785 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 72395 | Direct |
Footnotes
F1: On May 16, 2017 Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2: This transaction was executed in multiple trades at prices ranging from $74.99 to $75.58. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F3: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.